Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate CancerJune 5th 2013
In the wake of the approval of several novel treatments for prostate cancer, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.
New Developments in Oral Targeted Agents for Advanced Colorectal CancerMay 20th 2013
In September 2012, the FDA approved regorafenib as a salvage treatment for metastatic colorectal cancer (mCRC) previously treated with chemotherapy, an antivascular endothelial growth factor therapy, or an anti-EGFR therapy.
Numerous Drug Classes Studied for Use in Follicular and Other LymphomasMay 15th 2013
Follicular lymphoma is characterized by repeated treatment responses and then relapses and researchers will need to generate a growing list of drug choices to keep pace with patientsâ€™ needs.
A Guide to ASCO 2013: Key Targeted TrialsMay 14th 2013
In advance of the 2013 American Society of Clinical Oncology annual meeting, Targeted Therapy News spoke with this yearâ€™s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.